BIOGEN INC.
BIIB Health Care · Pharmaceuticals & BiotechnologyEach grade is a single reported quarter's assessment, never an average — a card shows the grade at the newest quarter in view, so it follows the period and range controls above. Latest scored quarter: 2026-06-30.
▼−5 over range · as of 2026-06-30
Revenue +3.4% YoY, earnings -84.6% YoY · sector avg 66
▲+12 over range · as of 2026-06-30
3.6% net margin, 4% return on equity, 27% free-cash-flow margin, profitable in 7 of last 8 quarters · sector avg 45
▼−14 over range · as of 2026-06-30
Net debt 3.2x EBITDA, 1.9x current ratio · sector avg 59
Trailing twelve months · ending 2026-06-30 · green = improving · click a row to chart it
Revenue $10.0B +0.9% CHARTED Gross margin 74.0% −1.5pp Operating margin — — Net margin 8.3% −5.5pp Net income $834.6M −39.2%Filings
TTM 23-09 → TTM 26-06 · following the period bar 15 match| Year | Q1 | Q2 | Q3 | FY |
|---|---|---|---|---|
| 2026 | 10-Q Q1 2026 | no filing | no filing | no filing |
| 2025 | 10-Q Q1 2025 | 10-Q Q2 2025 | 10-Q Q3 2025 | 10-K FY 2025 |
| 2024 | 10-Q Q1 2024 | 10-Q Q2 2024 | 10-Q Q3 2024 | 10-K FY 2024 |
| 2023 | 10-Q Q1 2023 | 10-Q Q2 2023 | 10-Q Q3 2023 | 10-K FY 2023 |
| 2022 | no filing | no filing | no filing | 10-K FY 2022 |
All 15 filings
10-K FY 2024 2025-02-12 Pro → 10-Q Q3 2024 2024-10-30 Pro → 10-Q Q2 2024 2024-08-01 Pro → 10-Q Q1 2024 2024-04-24 Pro → 10-K FY 2023 2024-02-14 Pro → 10-Q Q3 2023 2023-11-08 Pro → 10-Q Q2 2023 2023-07-25 Pro → 10-Q Q1 2023 2023-04-25 Pro → 10-K FY 2022 2023-02-15 Pro →Filing-level fact detail is a Pro feature. The grades and figures above are free. See Pro plans
Trends
| Period | Period end | Revenue |
|---|---|---|
| TTM 23-09 | 2023-09-30 | $10.0B |
| TTM 23-12 | 2023-12-31 | $9.8B |
| TTM 24-03 | 2024-03-31 | $9.7B |
| TTM 24-06 | 2024-06-30 | $9.7B |
| TTM 24-09 | 2024-09-30 | $9.6B |
| TTM 24-12 | 2024-12-31 | $9.7B |
| TTM 25-03 | 2025-03-31 | $9.8B |
| TTM 25-06 | 2025-06-30 | $10.0B |
| TTM 25-09 | 2025-09-30 | $10.1B |
| TTM 25-12 | 2025-12-31 | $9.9B |
| TTM 26-03 | 2026-03-31 | $9.9B |
| TTM 26-06 | 2026-06-30 | $10.0B |
| Period | Period end | Net income |
|---|---|---|
| TTM 23-09 | 2023-09-30 | $1.5B |
| TTM 23-12 | 2023-12-31 | $1.2B |
| TTM 24-03 | 2024-03-31 | $1.2B |
| TTM 24-06 | 2024-06-30 | $1.2B |
| TTM 24-09 | 2024-09-30 | $1.6B |
| TTM 24-12 | 2024-12-31 | $1.6B |
| TTM 25-03 | 2025-03-31 | $1.5B |
| TTM 25-06 | 2025-06-30 | $1.5B |
| TTM 25-09 | 2025-09-30 | $1.6B |
| TTM 25-12 | 2025-12-31 | $1.3B |
| TTM 26-03 | 2026-03-31 | $1.4B |
| TTM 26-06 | 2026-06-30 | $834.6M |
Grade history
Point-in-time: each period shows the grade of the quarter it ends at — grades are never summed or averaged across a window.
Hover to read every grade at a period · shared with the trends chart · axis fixed 0–100
| Period | Period end | Growth | Quality | Safety |
|---|---|---|---|---|
| TTM 23-09 | 2023-09-30 | 20 | 23 | 57 |
| TTM 23-12 | 2023-12-31 | 13 | 32 | 67 |
| TTM 24-03 | 2024-03-31 | 29 | 46 | 52 |
| TTM 24-06 | 2024-06-30 | 29 | 49 | 75 |
| TTM 24-09 | 2024-09-30 | 48 | 51 | 31 |
| TTM 24-12 | 2024-12-31 | 38 | 49 | 49 |
| TTM 25-03 | 2025-03-31 | 38 | 46 | 50 |
| TTM 25-06 | 2025-06-30 | 48 | 48 | 72 |
| TTM 25-09 | 2025-09-30 | 44 | 56 | 74 |
| TTM 25-12 | 2025-12-31 | 4 | 29 | 77 |
| TTM 26-03 | 2026-03-31 | 41 | 44 | 77 |
| TTM 26-06 | 2026-06-30 | 15 | 35 | 43 |